trial · primary record
Lorigerlimab
Metastatic Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2028-06-30 |
| Primary endpoint | To establish overall survival (OS) |
| Registry ID | NCT05475171 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:45:19.693Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05475171
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.